Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany.
EuroIntervention. 2013 May;9 Suppl R:R117-21. doi: 10.4244/EIJV9SRA20.
Catheter-based renal denervation (RDN) has been shown to reduce sympathetic nerve activity and blood pressure in patients with resistant hypertension. Increased central sympathetic activity is a main contributor to the pathophysiology of several important chronic cardiovascular diseases, including diabetes and the metabolic syndrome. Indeed several recently published pilot studies and case reports suggest beneficial effects of RDN on glucose metabolism in patients with resistant hypertension. This review highlights the background of approaching the renal sympathetic nerves as a potential new therapeutic option to improve glycaemic control in patients with resistant hypertension.
经导管肾去神经术（RDN）已被证明可降低抗药性高血压患者的交感神经活性和血压。中枢交感神经活性增加是包括糖尿病和代谢综合征在内的几种重要慢性心血管疾病的病理生理的主要原因。事实上，最近发表的几项试点研究和病例报告表明，RDN 对抗药性高血压患者的葡萄糖代谢有有益的影响。这篇综述强调了将肾交感神经作为一种潜在的新治疗选择，以改善抗药性高血压患者血糖控制的背景。
